Exicure, Inc., a biotechnology company, announced on August 1, 2024, that it has received a formal notice from the Nasdaq Hearings Panel, confirming the continuation of the company's listing on The Nasdaq Capital Market. This decision is contingent on Exicure demonstrating compliance with all applicable criteria for continued listing by September 16, 2024. The company, which has undergone recent restructuring and suspended its clinical and development activities, is actively working to meet the Panel's conditions to maintain its listing. Exicure is also exploring strategic alternatives to enhance stockholder value, considering its historical biotechnology assets and other opportunities. The company has cautioned that there is no guarantee of meeting the Panel's requirements within the set timeframe and acknowledges the risks of not being able to rectify existing listing deficiencies, facing additional deficiencies, and the potential delisting of its common stock from Nasdaq.

Exicure, Inc., a biotechnology company, announced on August 1, 2024, that it has received a formal notice from the Nasdaq Hearings Panel, confirming the continuation of the company's listing on The Nasdaq Capital Market. This decision is contingent on Exicure demonstrating compliance with all applicable criteria for continued listing by September 16, 2024. The company, which has undergone recent restructuring and suspended its clinical and development activities, is actively working to meet the Panel's conditions to maintain its listing. Exicure is also exploring strategic alternatives to enhance stockholder value, considering its historical biotechnology assets and other opportunities. The company has cautioned that there is no guarantee of meeting the Panel's requirements within the set timeframe and acknowledges the risks of not being able to rectify existing listing deficiencies, facing additional deficiencies, and the potential delisting of its common stock from Nasdaq.